Abeona therapeutics achieves target enrollment in pivotal phase 3 viital™ study of eb-101 in rdeb

Topline data from viital™ expected in the third quarter of 2022 topline data from viital™ expected in the third quarter of 2022
ABEO Ratings Summary
ABEO Quant Ranking